Inhibikase Therapeutics, Inc. (IKT) Cash Flow Statement
Inhibikase Therapeutics, Inc. (IKT) generated -$42.6M of operating cash flow over the twelve months to 2026-06-30, spent $0 on capital expenditure and had free cash flow of -$42.6M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
IKTInhibikase Therapeutics, Inc.Follow IKT — free
—
Price chart with a free account
- Market cap
- 221.9M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 12 Nov, in 19 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -14.3 | -17.4 | -18.1 | -19.1 | -27.8 | -42.6 | |
| Capital expenditure | — | 0.2 | 0.0 | 0.0 | 0.0 | -0.0 | |
| Free cash flow | — | -17.6 | -18.1 | -19.1 | -27.8 | -42.6 | |
| Stock-based compensation | 1.5 | 0.5 | 0.5 | 8.1 | 15.3 | — |
USD millions · SEC XBRL
Inhibikase Therapeutics, Inc. — questions
- What is Inhibikase Therapeutics, Inc.'s operating cash flow?
- -$42.6M over the twelve months to 2026-06-30.
- How much does Inhibikase Therapeutics, Inc. spend on capital expenditure?
- $0 over the twelve months to 2026-06-30.
- What is Inhibikase Therapeutics, Inc.'s free cash flow?
- -$42.6M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Inhibikase Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.